Adeno Associated Virus Vectors Manufacturing Market Size, Share, and Outlook (2024-2031)

<h2>Global Adeno Associated Virus Vectors Manufacturing Market is segmented By Method (In Vivo, In Vitro)&nbsp;By Application (Gene Therapy, Cell Therapy, Vaccine Production, Others)&nbsp;By Therapeutic Area (Genetic Disorders, Infectious Diseases, Neurological Disorders, Hematological Diseases, Ophthalmic Disorders, Others) By End-User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

<h3>Market Overview</h3>

<blockquote>
The Global adeno-associated virus vectors manufacturing market reached US$ YY&nbsp;million in 2023&nbsp;and is expected to reach US$ YY&nbsp;million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
</blockquote>

Adeno-associated viral (AAV) vectors are replication-defective, single-stranded DNA parvoviruses, which require a helper Ad for their replication. Site-specific or random AAV vector integration into the host cell genome, in the absence of a helper virus, results in long-term transgene expression. Additionally, adeno-associated viral vectors demonstrate high transduction efficiency in a broad range of quiescent and dividing target cells. In contrast to Ads, AAV vectors do not produce a significant immune response.&nbsp;

Moreover, adeno-associated viral vectors are more frequently used for gene therapy for genetic diseases and cancer. In addition, adeno-associated virus vector-mediated gene delivery is also approved for the treatment of inherited blindness and spinal muscular atrophy, long-term therapeutic effects and other rare diseases, including hemophilia and Duchenne muscular dystrophy. They are also considered in cell therapy and vaccine production to treat many diseases.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			YY%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size&nbsp;
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Method, Application, Therapeutic Area and End-User
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<h3>Market Dynamics: Drivers</h3>

Increasing adoption of adeno-associated viral vectors

The increasing adoption of adeno-associated viral vectors is expected to drive the market over the forecast period. The increasing adoption leads to an increasing focus on launching more manufacturing platforms. For instance, on May 16, 2023, AGC Biologics launched its BravoAAV and ProntoLVV viral vector platforms. Leveraging three decades of Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience, AGC Biologics&rsquo; new platforms offer fast, efficient and reproducible clinical and commercial GMP production and release.&nbsp;

Additionally, on October 10, 2022, Charles River Laboratories International, Inc. launched its nAAVigation Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform that streamlines the pathway to GMP AAV vector manufacturing without the need for significant process development.&nbsp;

Moreover, the adeno-associated viral vectors are mostly used to treat many diseases, this further increases the adoption of adeno-associated virus vectors. For instance, on March 02, 2023, the first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna, Spark Therapeutics vision loss cure, and Zolgensma, Novartis&rsquo; spinal muscular atrophy treatment. In addition, they brought about a surge in demand for gene therapy delivery technologies. The surge is ongoing. Currently, it is stimulating innovation in vector design and manufacturing.

Furthermore, adeno-associated virus vectors are most commonly applicable for gene therapy, which also further increases the adoption. For instance, on March 9, 2023, Charles River Laboratories International, Inc. launched its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.

Further, the increasing prevalence of genetic, infectious, neurological, ophthalmic and other chronic disorders, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development novel therapies and vaccines are the factors expected to drive the market over the forecast period.

<h3>Restraints</h3>

Factors such as high manufacturing costs, lack of skilled professionals and limited cloning capacity are expected to hamper the market.&nbsp;

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/adeno-associated-virus-vectors-manufacturing-market" target="_blank">Request for Sample</a>

<h2>&nbsp;</h2>

<h3>Segment Analysis</h3>

The global adeno-associated virus vectors manufacturing market is segmented based on method, application, therapeutic area, end-user and region.

The gene therapy segment accounted for approximately 43.2% of the adeno-associated virus vectors manufacturing market share

The gene therapy segment is expected to hold the largest market share over the forecast period. Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Adeno-associated virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. Many companies are focussing on adeno-associated virus vector manufacturing for gene therapy.

For instance, on February 23, 2021, SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene &amp; cell therapy, signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.

Additionally, on August 1, 2023, Waters Corporation introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters XBridge Premier GTx BEH SEC columns double the speed of measuring the potency and safety of AAVs and optimize the manufacturing of these novel gene delivery vehicles.

Moreover, adeno-associated virus vectors helps researchers for developing gene therapies to treat many serious disorders. For instance, in November 2022, PerkinElmer, Inc., a global leader committed to innovating for a healthier world, launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer.

<h3>Geographical Analysis</h3>

North America accounted for approximately 40.3% of the market share&nbsp;

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as biotechnology companies and pharmaceutical companies. The presence of major players actively focussing on manufacturing more advanced adeno-associated virus vectors by offering advantages such as cost-effectiveness.

For instance, on November 16, 2022, Thermo Fisher Scientific, the world leader in serving science, introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. It is the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.

Furthermore, increasing research activities in the region helps to manufacture more advanced virus vectors which are more advantageous for gene therapy. As research activities increase, gene therapies are developed more precisely by offering wide treatment options for many diseases, which results in better patient outcomes.

For instance, on February 15, 2022, Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 &ndash; were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors.&nbsp;

<h3>Competitive Landscape</h3>

The major global players in the adeno-associated virus vectors manufacturing market include Thermo Fisher Scientific Inc., Oxford Biomedica PLC, Lonza Ltd, uniQure N.V., FUJIFILM Diosynth Biotechnologies, SIRION Biotech GmbH, Curigin Inc., Pfizer Inc., Genscript Biotech Corp and Vector Biolabs among others.&nbsp;

<h3>Key Developments</h3>

<ul>
	<li>On March 27, 2023, Avirmax CMC Inc. a cGMP-licensed contract development and manufacturing organization (CDMO), implemented its newly developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVF) developed for producing recombinant adeno-associated viral vectors (rAAV).</li>
	<li>On August 30, 2023, Quest Diagnostics granted FDA breakthrough designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Breakthrough Device Designation is an FDA process designed to expedite the development and review of certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.</li>
	<li>On June 15, 2022, Exothera SA collaborated with LogicBio Therapeutics and Polyplus-transfection SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.</li>
</ul>

<h3>COVID-19 Impact Analysis</h3>

The COVID-19 pandemic significantly impacted the global adeno-associated virus vectors manufacturing market. The pandemic has created a surge in demand for adeno-associated viral vectors, particularly in the development and production of COVID-19 vaccines. The urgent need for large-scale manufacturing of these vectors to support vaccine development has led to increased demand.

For instance, according to the National Institute of Health (NIH), 2022, based on the study, they developed a type 9 adeno-associated virus vectored vaccine candidate expressing a dimeric receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S protein) and evaluated its immunogenicity in a murine model. The vaccine candidate, named AAV9-RBD virus, was constructed by inserting a signal peptide to the N-terminus of two copies of RBD, spaced by a linker, into the genome of a type 9 adeno-associated virus.

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global adeno-associated virus vectors manufacturing market segmentation based on method, application, therapeutic area, end-user and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous data points of adeno-associated virus vectors manufacturing market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global adeno-associated virus vectors manufacturing market report would provide approximately 69 tables, 71 figures, and 188 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Method</li>
		<li>Snippet by Application</li>
		<li>Snippet by Therapeutic Area</li>
		<li>Snippet by End-User</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing Adoption of Adeno-Associated Viral Vectors</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>High Manufacturing Costs</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Pipeline Analysis</li>
		<li>Unmet Needs</li>
		<li>Patent Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID</li>
			<li>Scenario During COVID</li>
			<li>Scenario Post COVID</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Method</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Attractiveness Index, By Method</li>
		</ol>
		</li>
		<li>In Vivo*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>In Vitro&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Gene Therapy*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Cell Therapy</li>
		<li>Vaccine Production</li>
		<li>Others&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Therapeutic Area</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Attractiveness Index, By Therapeutic Area</li>
		</ol>
		</li>
		<li>Genetic Disorders*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Infectious Diseases</li>
		<li>Neurological Disorders</li>
		<li>Hematological Diseases</li>
		<li>Ophthalmic Disorders</li>
		<li>Others&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Attractiveness Index, By End-User</li>
		</ol>
		</li>
		<li>Pharmaceutical Companies*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Biotechnology Companies</li>
		<li>Academic and Research Institutes</li>
		<li>Others&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Method</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Thermo Fisher Scientific Inc.*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Oxford Biomedica PLC</li>
		<li>Lonza Ltd</li>
		<li>uniQure N.V.</li>
		<li>FUJIFILM Diosynth Biotechnologies</li>
		<li>SIRION Biotech GmbH</li>
		<li>Curigin Inc.</li>
		<li>Pfizer Inc.</li>
		<li>Genscript Biotech Corp</li>
		<li>Vector Biolabs&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2023, 2027 &amp; 2031 (US$ Million)

Table 7 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 8 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2023, 2027 &amp; 2031 (US$ Million)

Table 9 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 10 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2023, 2027 &amp; 2031 (US$ Million)

Table 11 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 12 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2023, 2027 &amp; 2031 (US$ Million)

Table 13 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 15 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 17 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 18 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 19 North America Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 22 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 23 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 24 South America Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 27 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 29 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 37 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 38 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 39 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Thermo Fisher Scientific Inc.: Overview

Table 41 Thermo Fisher Scientific Inc.: Product Portfolio

Table 42 Thermo Fisher Scientific Inc.: Key Developments

Table 43 Oxford Biomedica PLC: Overview

Table 44 Oxford Biomedica PLC: Product Portfolio

Table 45 Oxford Biomedica PLC: Key Developments

Table 46 Lonza Ltd: Overview

Table 47 Lonza Ltd: Product Portfolio

Table 48 Lonza Ltd: Key Developments

Table 49 uniQure N.V.: Overview

Table 50 uniQure N.V.: Product Portfolio

Table 51 uniQure N.V.: Key Developments

Table 52 FUJIFILM Diosynth Biotechnologies: Overview

Table 53 FUJIFILM Diosynth Biotechnologies: Product Portfolio

Table 54 FUJIFILM Diosynth Biotechnologies: Key Developments

Table 55 SIRION Biotech GmbH: Overview

Table 56 SIRION Biotech GmbH: Product Portfolio

Table 57 SIRION Biotech GmbH: Key Developments

Table 58 Curigin Inc.: Overview

Table 59 Curigin Inc.: Product Portfolio

Table 60 Curigin Inc.: Key Developments

Table 61 Pfizer Inc.: Overview

Table 62 Pfizer Inc.: Product Portfolio

Table 63 Pfizer Inc.: Key Developments

Table 64 Genscript Biotech Corp: Overview

Table 65 Genscript Biotech Corp: Product Portfolio

Table 66 Genscript Biotech Corp: Key Developments

Table 67 Vector Biolabs: Overview

Table 68 Vector Biolabs: Product Portfolio

Table 69 Vector Biolabs: Key Developments

List of Figures

Figure 1 Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 2 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 3 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 4 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 5 Global Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 6 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Region, 2022 &amp; 2031 (%)

Figure 7 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Method, 2022-2031 (%)

Figure 8 In Vivo Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 9 In Vitro Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 10 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 11 Gene Therapy Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 12 Cell Therapy Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 13 Vaccine Production Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 14 Others Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 15 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Therapeutic Area, 2022-2031 (%)

Figure 16 Genetic Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 17 Infectious Diseases Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 18 Neurological Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 19 Hematological Diseases Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 20 Ophthalmic Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 21 Others Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 22 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 23 Pharmaceutical Companies End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 24 Biotechnology Companies End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 25 Academic and Research Institutes End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 26 Others End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 27 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 28 North America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 29 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 30 Europe Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 31 South America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 32 Middle East and Africa Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 33 North America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 34 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 35 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 36 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 37 North America Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 38 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 &amp; 2031 (%)

Figure 39 South America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 40 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 41 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 42 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 43 South America Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 44 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 &amp; 2031 (%)

Figure 45 Europe Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 46 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 47 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 48 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 49 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 50 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 &amp; 2031 (%)

Figure 51 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 52 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 53 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 54 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 55 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 56 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 &amp; 2031 (%)

Figure 57 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 58 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 &amp; 2031 (%)

Figure 59 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 &amp; 2031 (%)

Figure 60 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 &amp; 2031 (%)

Figure 61 Middle East &amp; Africa Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 62 Thermo Fisher Scientific Inc.: Financials

Figure 63 Oxford Biomedica PLC: Financials

Figure 64 Lonza Ltd: Financials

Figure 65 uniQure N.V.: Financials

Figure 66 FUJIFILM Diosynth Biotechnologies: Financials

Figure 67 SIRION Biotech GmbH: Financials

Figure 68 Curigin Inc.: Financials

Figure 69 Pfizer Inc.: Financials

Figure 70 Genscript Biotech Corp: Financials

Figure 71 Vector Biolabs: Financials

Adeno Associated Virus Vectors Manufacturing Market Size, Share, and Outlook (2024-2031)

Viral Vector Manufacturing Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 January 10

Starting from

Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, Demand, Trends, Industry and Market Forecast (2024-2031)

Published: 2024 January 11

Starting from

Viral Vector Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 February 22

Starting from

Gene Therapy Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Published: 2024 January 10

Starting from